14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MCRB vs MESO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MCRB carries a Unified Composite Score of 50.6/100 (HOLD) at $1.42 (10.8x Forward P/E, -3115.1% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).
Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -3115.1% operating margin) and revenue trajectory (+390.7% vs. +68.9% YoY).
Technical & Structure Timing Caution: MCRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MCRB vs MESO. Trailing 12-month operating profitability (MCRB -3115.1% vs MESO -42.6%) and valuation multiples (MCRB 10.8x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MCRB vs MESO Key Questions & Quantitative Answers
As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Seres Therapeutics, Inc. (MCRB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MCRB carries a Unified Composite Score of 50.6/100 (HOLD) at $1.42 (10.8x Forward P/E, -3115.1% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Composite vs. Pillar Nuance: While MCRB currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -3115.1% operating margin) and revenue trajectory (+390.7% vs. +68.9% YoY). Technical & Structure Timing Caution: MCRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MESO leads the Growth & Scale pillar: MCRB posts +68.9% YoY revenue growth and -91.9% YoY earnings growth on $2.1M TTM revenue (N/A gross margin, -3115.1% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, MCRB generates $2.1M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, MCRB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.
MCRB screens cheaper on headline valuation multiples. MCRB trades at 10.8x Forward P/E, 10.8x Trailing P/E, N/M PEG, and 15.1x EV/Revenue (unreported EBITDA margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MCRB (-144.3% ROE) versus MESO (-9.9% ROE) capital efficiency.
In options market volatility and institutional positioning, MCRB carries 95.5% implied volatility (22nd %ile, Compressed (<25th %ile)), a 104.33x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 97% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.